



Technology: Tocilizumab is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor that inhibits IL-6 signaling and hinders IL-6’s pro-inflammatory effects.

Tocilizumab Timeline



Tocilizumab Challenged Claim Types in IPR and Litigation*



*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints. Joinder counted separately.

Spotlight On:
Tocilizumab

February 28, 2025

	<i>Fresenius Kabi v. Chugai</i> IPR2021-01024 Settled after institution	<i>Fresenius Kabi v. Chugai</i> IPR2021-01025 Settled after institution	<i>Fresenius Kabi v. Chugai</i> IPR2021-01288, IPR2021-01542 Settled after institution	<i>Fresenius Kabi v. Chugai</i> IPR2021-01336 Settled after institution	<i>Fresenius Kabi v. Chugai</i> IPR2022-00201 Settled after institution	<i>Celltrion v. Chugai</i> IPR2022-00578 Final Written Decision (All challenged claims unpatentable); Appeal 24-1115 voluntarily dismissed	<i>Celltrion v. Chugai</i> IPR2022-00579 Final Written Decision (All challenged claims unpatentable); Appeal 24-1111 voluntarily dismissed	<i>Fresenius Kabi v. Chugai</i> IPR2022-01065 Settled before institution	<i>Genentech v. Biogen</i> 1:23-cv-11573 (D. Mass.) Settled
7,332,289									x
7,521,052	x								x
8,398,980									x
8,512,983									x
8,574,869									x
8,580,264			x			x			
8,734,800									x
9,714,293									x
9,750,752					x				
9,902,777									x
10,017,732									x
10,231,981								x	
10,336,983									x
10,501,769									x
10,662,237									x
10,676,710									x
10,744,201		x							x
10,829,732									x
10,874,677				x			x		
10,982,003									x
11,021,728									x
11,078,294									x
11,136,610									x
11,377,678									x